A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Patnaik, Amita ; Haluska, Paul ; Tolcher, Anthony W ; Erlichman, Charles ; Papadopoulos, Kyriakos P ; Lensing, Janet L ; Beeram, Muralidhar ; Molina, Julian R ; Rasco, Drew W ; Arcos, Rebecca R ; Kelly, Claudia S ; Wijayawardana, Sameera R ; Zhang, Xuekui ; Stancato, Louis F ; Bell, Robert ; Shi, Peipei ; Kulanthaivel, Palaniappan ; Pitou, Celine ; Mulle, Lynette B ; Farrington, Daphne L ; Chan, Edward M ; Goetz, Matthew P

Clinical cancer research, 2016-03, Vol.22 (5), p.1095-1102 [Periódico revisado por pares]

United States

Texto completo disponível